These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 18808743)

  • 1. Spotlight on anti-CD25: daclizumab in MS.
    Schippling DS; Martin R
    Int MS J; 2008 Sep; 15(3):94-8. PubMed ID: 18808743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-CD25 (daclizumab) monoclonal antibody therapy in relapsing-remitting multiple sclerosis.
    Martin R
    Clin Immunol; 2012 Jan; 142(1):9-14. PubMed ID: 22284868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Humanized anti-CD25 antibody treatment with daclizumab in multiple sclerosis.
    Martin R
    Neurodegener Dis; 2008; 5(1):23-6. PubMed ID: 18075271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Daclizumab in treatment of multiple sclerosis patients.
    Ali EN; Healy BC; Stazzone LA; Brown BA; Weiner HL; Khoury SJ
    Mult Scler; 2009 Feb; 15(2):272-4. PubMed ID: 19136546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta.
    Wynn D; Kaufman M; Montalban X; Vollmer T; Simon J; Elkins J; O'Neill G; Neyer L; Sheridan J; Wang C; Fong A; Rose JW;
    Lancet Neurol; 2010 Apr; 9(4):381-90. PubMed ID: 20163990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Daclizumab for the treatment of adults with relapsing forms of multiple sclerosis.
    Osherov M; Milo R
    Expert Rev Clin Pharmacol; 2017 Oct; 10(10):1037-1047. PubMed ID: 28803486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey.
    Waldmann TA
    J Clin Immunol; 2007 Jan; 27(1):1-18. PubMed ID: 17216565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo maintenance of human regulatory T cells during CD25 blockade.
    Huss DJ; Mehta DS; Sharma A; You X; Riester KA; Sheridan JP; Amaravadi LS; Elkins JS; Fontenot JD
    J Immunol; 2015 Jan; 194(1):84-92. PubMed ID: 25416807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Daclizumab (anti-CD25) in multiple sclerosis.
    Pfender N; Martin R
    Exp Neurol; 2014 Dec; 262 Pt A():44-51. PubMed ID: 24768797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results.
    Rose JW; Burns JB; Bjorklund J; Klein J; Watt HE; Carlson NG
    Neurology; 2007 Aug; 69(8):785-9. PubMed ID: 17709711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study.
    Gold R; Radue EW; Giovannoni G; Selmaj K; Havrdova E; Stefoski D; Sprenger T; Montalban X; Cohan S; Umans K; Greenberg SJ; Ozen G; Elkins J
    BMC Neurol; 2016 Jul; 16():117. PubMed ID: 27461166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Daclizumab for the treatment of relapsing-remitting multiple sclerosis.
    Herwerth M; Hemmer B
    Expert Opin Biol Ther; 2017 Jun; 17(6):747-753. PubMed ID: 28286970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Daclizumab and its use in multiple sclerosis treatment.
    Milo R; Osherov M
    Drugs Today (Barc); 2017 Jan; 53(1):7-18. PubMed ID: 28387383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic drug evaluation of daclizumab for the treatment of relapsing-remitting multiple sclerosis.
    Patti F; Chisari CG; D'Amico E; Zappia M
    Expert Opin Drug Metab Toxicol; 2018 Mar; 14(3):341-352. PubMed ID: 29363337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta.
    Bielekova B; Richert N; Howard T; Blevins G; Markovic-Plese S; McCartin J; Frank JA; Würfel J; Ohayon J; Waldmann TA; McFarland HF; Martin R
    Proc Natl Acad Sci U S A; 2004 Jun; 101(23):8705-8. PubMed ID: 15161974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A critical appraisal of daclizumab use as emerging therapy in multiple sclerosis.
    D'Amico E; Messina S; Caserta C; Patti F
    Expert Opin Drug Saf; 2015 Jul; 14(7):1157-68. PubMed ID: 25826609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
    Kappos L; Wiendl H; Selmaj K; Arnold DL; Havrdova E; Boyko A; Kaufman M; Rose J; Greenberg S; Sweetser M; Riester K; O'Neill G; Elkins J
    N Engl J Med; 2015 Oct; 373(15):1418-28. PubMed ID: 26444729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Multiple sclerosis: between wish and reality].
    Kümpfel T; Hohlfeld R
    MMW Fortschr Med; 2005 May; 147 Spec No 2():83-5. PubMed ID: 15968879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Daclizumab: Development, Clinical Trials, and Practical Aspects of Use in Multiple Sclerosis.
    Baldassari LE; Rose JW
    Neurotherapeutics; 2017 Oct; 14(4):842-858. PubMed ID: 28707278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Review of daclizumab and its therapeutic potential in the treatment of relapsing-remitting multiple sclerosis.
    Reardon J; Perumal JS
    Drug Des Devel Ther; 2013; 7():1187-93. PubMed ID: 24143075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.